Topoisomerase poisons such as the epipodophyllotoxin etoposide are widely used effective cytotoxic anticancer agents. However, they are associated with the development of therapy-related acute myeloid leukemias (t-AMLs), which display characteristic balanced chromosome translocations, most often involving the mixed lineage leukemia (MLL) locus at 11q23. MLL translocation breakpoints in t-AMLs cluster in a DNase I hypersensitive region, which possesses cryptic promoter activity, implicating transcription as well as topoisomerase II activity in the translocation mechanism. We find that 2-3% of MLL alleles undergoing transcription do so in close proximity to one of its recurrent translocation partner genes, AF9 or AF4, consistent with their sharing transcription factories. We show that most etoposide-induced chromosome breaks in the MLL locus and the overall genotoxicity of etoposide are dependent on topoisomerase IIβ, but that topoisomerase IIα and -β occupancy and etoposide-induced DNA cleavage data suggest factors other than local topoisomerase II concentration determine specific clustering of MLL translocation breakpoints in t-AML. We propose a model where DNA double-strand breaks (DSBs) introduced by topoisomerase IIβ into pairs of genes undergoing transcription within a common transcription factory become stabilized by antitopoisomerase II drugs such as etoposide, providing the opportunity for illegitimate end joining and translocation.
Model for MLL translocations in therapy-related leukemia involving topoisomerase IIβ-mediated DNA strand breaks and gene proximity Topoisomerase poisons such as the epipodophyllotoxin etoposide are widely used effective cytotoxic anticancer agents. However, they are associated with the development of therapy-related acute myeloid leukemias (t-AMLs), which display characteristic balanced chromosome translocations, most often involving the mixed lineage leukemia (MLL) locus at 11q23. MLL translocation breakpoints in t-AMLs cluster in a DNase I hypersensitive region, which possesses cryptic promoter activity, implicating transcription as well as topoisomerase II activity in the translocation mechanism. We find that 2-3% of MLL alleles undergoing transcription do so in close proximity to one of its recurrent translocation partner genes, AF9 or AF4, consistent with their sharing transcription factories. We show that most etoposide-induced chromosome breaks in the MLL locus and the overall genotoxicity of etoposide are dependent on topoisomerase IIβ, but that topoisomerase IIα and -β occupancy and etoposide-induced DNA cleavage data suggest factors other than local topoisomerase II concentration determine specific clustering of MLL translocation breakpoints in t-AML. We propose a model where DNA double-strand breaks (DSBs) introduced by topoisomerase IIβ into pairs of genes undergoing transcription within a common transcription factory become stabilized by antitopoisomerase II drugs such as etoposide, providing the opportunity for illegitimate end joining and translocation.
TOP2 | acute leukemia | nuclear organization T herapy-related acute leukemia is an unfortunate side effect of chemotherapy used to treat primary cancers. Chromosomal translocations are a crucial early event in many leukemias, but the mechanism(s) by which these translocations occur are not fully understood (1, 2) . Chromosome translocation requires double-strand breaks (DSBs) in each chromosome and close proximity of the breaks, allowing aberrant joining of the heterologous ends. Some debate has existed as to whether chromatin fibers need to be juxtaposed at the time of DNA damage or whether breaks formed at distal sites are able to come together to generate translocations. However, the former model is supported by the positional stability of breaks, the limited mobility of chromatin fibers (3) (4) (5) , and by the relationship between translocation frequencies and average interphase proximity of the loci involved (6, 7) . Several mechanisms of DSB formation contribute to events leading to leukemias and lymphomas (1, 2), but therapy-related acute myeloid leukemia (t-AML) with balanced reciprocal translocation is strongly associated with prior exposure to a class of widely used anticancer drugs known as topoisomerase poisons, which includes etoposide (8) . Balanced chromosome translocations involving the mixed lineage leukemia locus (MLL) at 11q23 account for approximately one-third of t-AML translocations (8) and appear with a short latency period following chemotherapy with topoisomerase poisons (9).
Estrogen exposure in utero has also been linked to MLL rearrangements (10) .
Topoisomerase II plays a role in replication, transcription, chromosome condensation, and segregation. The dimeric enzyme cleaves DNA at a pair of phosphodiester bonds 4 bp apart to generate a staggered double-strand break termed a cleavage complex in which the enzyme remains covalently bound to the ends of the DSB via a 5′-phosphotyrosyl linkage. A second DNA segment is passed through this enzyme-bridged "DNA gate" and the break is resealed. Topoisomerase poisons inhibit this religation step, resulting in formation of an unusual class of DSB covalently linked to topoisomerase protein via the 5′-phosphotyrosyl linkage. Efficient repair of topoisomerase II poison-mediated DNA damage requires NHEJ (11) (12) (13) , and accumulation of topoisomerase II-mediated DNA damage leads to cell death.
Chromosomal breakpoints involved in MLL translocations fall within an 8-kb breakpoint cluster region (BCR). Those derived from therapy related acute leukema (t-AL) and neonatal acute leukemias are concentrated at the telomeric 1 kb of this region ( Fig. S1 and refs. within), associated with an area of DNase I hypersensitivity, cryptic promoter activity, and etoposide-induced cleavage (14, 15) . DNase I hypersensitive sites are also present in the BCRs of other t-AML translocation-associated genes including AF9, AF4 (Fig. S2) , RUNX1, ETO, and RARA. DNase I hypersensitivity marks promoters and other transcriptional regulatory elements and transcription-associated recombination (TAR) has been previously described but the mechanisms are poorly understood (16, 17) . Transcription occurs at dynamic structures called factories or hubs (18) . The focal nature of transcription means that transcribing genes and their regulatory elements can be positioned in close proximity to other genes and it is likely that this juxtaposition contributes to the observed influence of genome organization on partner selection in chromosomal rearrangements (19, 20) . DNA topoisomerase IIβ regulates transcription in response to estrogen and other nuclear hormones in a manner that appears to involve a transient DSB (21) (22) (23) . Similarly, topoisomerase IIβ negatively regulates retinoic acid action (24) and retinoic acid induces protein-linked DSBs in myeloid cells (25) . Topoisomerase II is also believed to be required to relieve positive supercoiling ahead of elongating RNA polymerase (26) and for efficient transcription on chromatin templates (27) , processes which also involve DNA cleavage. This led us to propose a model for the etiology of MLL translocations in t-AML where transcription-associated DSBs introduced by topoisomerase IIβ into MLL and its translocation partners are stabilized by a topoisomerase poison such as etoposide. Recombination is then facilitated by their close proximity in individual transcription factories. Topoisomerase IIβ is reported to be corecruited with components of the NHEJ machinery to promoters (21) , suggesting that aberrant repair can occur in the context of shared transcription factories (Fig. 1A) .
Results
To investigate the validity of this model, we examined the relative spatial distribution of actively transcribing alleles of MLL and two of its most frequent recurrent t-AML translocation partners (AF4 and AF9). For comparison, three other genes were included in this analysis ( Fig. 1 B and C) . ELL is a recurrent MLL translocation partner, which is rarely involved in t-AML. DCP1A has been reported in a single case of AML (28) and UGCG is a control gene that has never been reported to be involved in an MLL translocation. Nascent transcripts were visualized by RNA-FISH in a human CD34 + myeloid leukemia cell line (KG1; Fig. 1 ) apparently derived from a myeloid-lymphoid progenitor and which possesses an almost normal karyotype with no karyotype abnormalities in the chromosome regions of the genes being examined (29) . We selected this cell line because it can be considered a surrogate for the precursor from which t-AML is presumed to arise. These experiments were also carried out using a pre-B leukemia cell line (Nalm-6) and a matched line null for TOP2B (Nalm-6 TOP2B−/− ) (12) . RNA-FISH probes were derived from MLL, AF4, AF9, ELL, DCP1A, or UGCG intron sequences (SI Materials and Methods). In KG1 cells, 2.6% of all MLL nascent transcripts coincided with a site of AF4 transcription. Similarly, 2.3% of all expressed MLL alleles coincided with a site of AF9 transcription (Fig. 1 B-F) . Considering the resolving power of confocal microscopy (200-300 nm in the x-y plane), genes engaged with a common transcription factory (diameter ∼90 nm) would generate overlapping signals by these criteria. Furthermore, we found that 5.7% of MLL nascent transcripts were localized within 1 μm of a site of AF4 transcription, and 4.2% within 1 μm of an active AF9 allele ( Fig. 1 D and E) . Although 1-μm distance is larger than the separation of loci engaged with a common transcription factory, it is estimated to be the radius of the volume that a chromosome segment can "explore" by constrained diffusion (4, 5) . Association of transcription units with RNA polymerases/transcription factories is dynamic and genes presumably disengage upon transcriptional termination and do not necessarily encounter the same factory for the next round of transcription. AF4 and AF9 nascent transcripts were found within 1 μm of a site of MLL transcription at about the same frequency as ELL or DCP1A, but at a significantly higher frequency than the control gene UGCG (P < 0.05). Overlapping MLL/AF4 and MLL/AF9 nascent RNA signals were present significantly more frequently than either DCP1A or UGCG (fourto fivefold, P < 0.05). Comparable data were obtained for Nalm-6 cells and for Nalm-6 cells null for topoisomerase IIβ (Nalm-6 TOP2B−/− ; Fig. 1 G and H). Notably, however, the frequency of MLL-AF4 or MLL-AF9 juxtaposition was lower for Nalm-6 TOP2B−/− than for the wild-type cells. This did not reach significance for AF4, but was significant for AF9 (P < 0.05). Etoposide treatment did not significantly affect the colocalization frequency of MLL and AF9 loci (Fig. 1I) . Thus, for KG1 and Nalm-6 cells, ∼5% of all actively transcribing MLL loci were close enough to a site of AF4 transcription that these alleles either share a common transcription factory or could associate with a common transcription factory in a subsequent transcription cycle. All of the genes analyzed were expressed with similar frequencies in KG1 cells ( Fig. 1 F and H) . Despite the close proximity of MLL loci with AF4 or AF9 in some cells, we could not detect this interaction using 3C analysis (Fig. S3 ). This is perhaps not surprising as the loci are in very close proximity in only 2-3% of cells, and secondly, the estimated diameter of a transcription factory (∼90 nm) may not allow efficient cross-linking of the separate chromatin fragments. Indeed, in a related study Osborne et al. (30) , report that whereas transcribed Uros and Igf2 loci colocalize with the linked Hbb-b1 locus in 41 and 60% of cells, respectively, Uros only yields ligation products after extended cross-linking, and Igf2 did not yield a product even under these conditions.
The model also predicts that breaks at the MLL locus that lead to translocations should preferentially involve the -β isoform of topoisomerase II, because it is specifically this isoform that is implicated in transcription-coupled DSB generation. In contrast, topoisomerase IIα is held to be the more important target for etoposide in the context of cytotoxicity. In agreement, TOP2A heterozygous knockout Nalm-6 cells are substantially resistant to etoposide in clonogenic assays, whereas the sensitivity of homozygous TOP2B knockout cells differs only slightly from WT (12) . We used DNA-FISH with a "break-apart" rearrangement probe to quantify etoposide-induced chromosome breaks at the MLL locus. To directly assess the role of topoisomerase IIβ in generating breaks in the MLL locus we used Nalm-6 and Nalm-6 TOP2B−/− cells (12) . Etoposide induced approximately sevenfold more breaks in the MLL locus in the Nalm-6 cells than in Nalm-6 TOP2B−/− cells ( Fig. 2 A and B) . Although the frequency of chromosomal breaks induced at the MLL locus was substantially reduced in the absence of topoisomerase IIβ (P = 0.002), it was not completely abolished and a small but significant (P = 0.02) increase was still observed, suggesting that topoisomerase IIα can cause breakage at this locus in the absence of topoisomerase IIβ, albeit with a lower frequency. Thus, whereas topoisomerase IIα is the more significant isozyme with regard to cytotoxicity in these cell lines, the majority of breaks at the MLL locus, that can be detected by DNA-FISH, are dependent upon topoisomerase IIβ. We repeated the DNA-FISH experiment with the topoisomerase IIα-specific poison NK314 at an equitoxic concentration. A small number of breaks were detected in both WT and Nalm-6 TOP2B−/− cells, in both cases approximately equal in frequency to those induced by etoposide in the TOP2B −/− cells (Fig.  2C) . Thus, topoisomerase IIβ has a major role in generating etoposide-induced breaks at the MLL locus, despite the greater role that can be attributed to topoisomerase IIα in mediating cytoxicity.
The data discussed above could result from unusually high rates of topoisomerase IIβ-mediated (but not α-mediated) cleavage in the MLL locus compared with the genome as a whole, or alternatively, it could result from a specific propensity of topoisomerase IIβ-mediated cleavage events to lead to chromosomal breaks and rearrangements. To determine the contribution made by topoisomerase IIβ to etoposide-induced genome-wide genotoxicity, we carried out micronuclei (MN) assays in Nalm-6, Nalm-
, and in Nalm-6 TOP2A+/− cells. MN can result from acentric chromosome fragments that fail to become incorporated into daughter nuclei at telophase and the MN assay is an established method for assessing chromosome damage in toxicology studies (31) . Background MN levels were not significantly different between the three cell lines. Etoposide treatment (100 nM) resulted in a 2.3-fold increase in the percentage of WT cells containing micronuclei, consistent with its known genotoxicity. Nalm-6
TOP2A+/− cells behaved in the same way as wild-type cells, whereas in Nalm-6 TOP2B−/− cells there was no significant difference in the MN frequency between control and etoposide-treated cells (Fig. 3) . Thus, the genotoxic effects of etoposide appear to be mediated predominantly by topoisomerase IIβ.
The DNA-FISH and MN assays described above relate to chromosome breaks that have failed to be repaired before mitosis or that have been repaired aberrantly. To determine whether topoisomerase IIβ status affects the extent of immediate etoposide-induced DNA damage generated across the genome, we used histone H2AX phosphorylation as an assay for DNA doublestrand breaks (Fig. 4) . To generate consistent and countable γH2AX foci, cells were treated with etoposide at a concentration of 5 μM for a short time period (2 h). Under these conditions an average value of 40 foci were generated in WT Nalm-6 cells and there was no significant difference between the numbers of foci observed in WT, Nalm-6
, or Nalm-6 TOP2A+/− cells (Fig.  4A) . Similarly, no significant difference was observed when γH2AX fluorescence values were compared (Fig. 4B) . This is consistent with our previous findings in murine Top2B −/− cells (32). Thus, whereas cells lacking topoisomerase IIβ exhibit far fewer etoposide-mediated chromosome breaks in the MLL locus than wild-type cells, and do not exhibit an increase in MN frequency when exposed to etoposide, global genomic DSBs are generated with equal efficiency in WT or TOP2B −/− cells. The model described above requires that topoisomerase IIβ can associate with the chromatin of the genes that become translocated. To determine the distribution of topoisomerase IIα and IIβ over the MLL and AF9 genes, we used chromatin immunoprecipitation (ChIP) using specific antitopoisomerase IIα or IIβ antibodies previously validated for ChIP (Fig. S4 and SI Materials and Methods). ChIP experiments sampling multiple regions across the MLL and AF9 loci revealed the presence of topoisomerase IIα and -β in chromatin at each of the positions sampled, including within the BCRs of each gene (Figs. S5 and S6). However, neither topoisomerase IIα, nor IIβ appeared overrepresented at the telomeric end of the MLL BCR, which corresponds to most reported t-AL breakpoints, or in the BCRs of AF9. The same sites were sampled in cells treated with 100 μM etoposide for 60 min, which results in a large increase in stabilized covalent topoisomerase IIα and IIβ DNA complexes (33). At the majority of sites sampled, etoposide treatment resulted in a modest increase in topoisomerase IIα and IIβ occupancy above nondrug-treated cells. Next we focused just on the telomeric end of the MLL BCR. This analysis used primer pair MLL1, which maps to MLL intron 7 (5′ of the BCR), primer pairs MLL7 and MLL7b, which flank a closely spaced cluster of breakpoints reported in therapy related and neonatal leukemia (Figs. 1 and 5A and Fig. S1 ). Primer pair MLL7 also overlaps with previously identified CTCF and DNase I peaks (Fig. S1) . A fourth primer pair, MLL8, maps to intron 12, downstream of the BCR. This analysis confirmed the occupancy of topoisomerase IIα and IIβ in chromatin at each of the four sites sampled (Fig. 5 B and C) . For both topoisomerase II isoforms, primer pair MLL8 yielded the greatest average percentage recovery compared with primer pair MLL1. This was significant for topoisomerase IIβ (P = 0.05), but did not reach significance for topoisomerase IIα. Etoposide treatment resulted in a modest increase of signal for both isoforms at each site, but these increases did not reach significance ( Fig. 5 B and C) . Sampling CTCF binding at the same positions confirmed the presence of a CTCF binding peak observed for GM12878 and K562 cells in ENCODE data (Figs. 5D and Fig.  S1 ). Consistent with the ENCODE data, the highest signal was obtained with primer pair MLL7. Because a fraction of CTCF has been reported to be in a protein complex with topoisomerase IIα (34) we examined whether etoposide treatment of cells, which induces high levels of topoisomerase-DNA covalent complexes, affected the binding of CTCF in this region. No difference in CTCF binding was observed comparing untreated to etoposide (100 μM) treated cells (Fig. 5D ).
Neither topoisomerase IIα or IIβ showed higher occupancy in the telomeric region of the MLL BCR (Fig. 5) . Next we used the fact that covalent topoisomerase II enzyme-bridged DSBs are stabilized and thus increased in number by topoisomerase poisons, to map in-cell cleavage sites for topoisomerase IIα and IIβ. Briefly, cells were treated with 100 μM etoposide for 60 min and topoisomerase IIα or IIβ immunoprecipitation was performed in the absence of cross-linker. Recovered DNA was thus enriched for sequences one or both ends of which terminate in a topoisomerase II phosphotyrosyl-linked adduct. Recovered DNA was subject to Illumina paired-end sequencing (see SI Materials and Methods for details). Ends of the resulting sequence reads (read ends) mapping to the MLL BCR were examined and compared with characterized translocation break sites. For both topoisomerase IIα and IIβ approximately twofold more read ends mapped to the MLL BCR when cells were treated with etoposide than in control cells (Fig. S7) . Several of the read ends fell within 10 bp of sequenced patient breakpoints (red arrows in Fig. S7 ). Notably, this includes an etoposide-induced topoisomerase IIβ read end (marked with an asterisk in Fig. S7 ) that corresponds directly to the cluster of therapy related and neonatal acute leukemia translocation sites marked I in Fig. S7  (RE_11b+VP16; Fig. S8 ) and to which etoposide cleavage has been previously mapped using a different methodology (35) .
Discussion
It is presumed that DNA damage introduced directly by topoisomerase II is central to the translocation mechanism in t-AMLs following topoisomerase poison treatment. We found that etoposide-mediated chromosome breakage at the MLL locus, as quantified by DNA-FISH, was greatly reduced in TOP2B −/− cells (Fig. 2) and etoposide genotoxicity as measured by micronucleus formation is topoisomerase IIβ dependent (Fig. 3) . In ChIP analysis, both isoforms of topoisomerase II were present in the chromatin of the MLL BCR but were not overrepresented in the telomeric end of the MLL BCR, which is associated with t-AL translocations. By immunoprecipitating non-cross-linked chromatin we isolated DNA fragments containing covalent topoisomerase-DNA complexes. Illumina sequencing of these fragments generated sequence reads whose ends correspond to ), or Nalm-6 TOP2A+/− cells were treated with etoposide (100 nM) or solvent alone and were scored for the presence of micronuclei. All significance values were derived using Student's t test. topoisomerase cleavage events. To our knowledge, this is the first report where topoisomerase II cleavage sites generated in living cells have been mapped in a way that distinguishes between the two isoforms. We compared the read ends with translocation break sites. Due to possible end resection and other events associated with aberrant repair, translocation break sites do not necessarily map exactly to positions of initial strand breaks. Therefore, we looked for read ends that were within 10 or 20 bp of a translocation breakpoint. A number of topoisomerase IIα and IIβ read ends met this criterion (Figs. S7 and S8 ). Most notably, this includes a topoisomerase IIβ cleavage site mapping to a hotspot of t-AL and neonatal acute leukemia translocation break sites designated cluster I in Fig. S7 . Interestingly, this cluster of translocation break sites is centered on an ATTA motif, which is also found in the etoposide-stabilized and topoisomerase IIβ-associated cleavage site reported in the pS2 promoter (Fig. S8 ) (21) . Although there is no strong consensus surrounding optimum topoisomerase II cleavage sites, there are some constraints (36) including an apparent preference for A/T residues in the +1 to +4 positions, which constitute the 5′ overhang. Reciprocal topoisomerase II cleavage events in MLL and at sites in translocation partner genes could generate homologous single-stranded overhangs that anneal to form breakpoint junction sequences. This may typically involve processing to reveal microhomologies, although in one analyzed case, annealing appears to have occurred between TAATTA sequences in MLL (in subcluster I; Fig. S7 ) and in AF9 without processing (37) . Thus, etoposide can induce DNA cleavage events that correspond to identified MLL translocation break sites and some of these break sites are centered on a sequence motif (ATTA) previously identified as an etoposide-stabilized topoisomerase II cleavage site in the pS2 promoter.
The frequencies for the sharing of sites of transcription between MLL and AF9 or AF4 were lower than was reported in murine cells for the frequent B-cell translocation partners Myc and IgH (20) , but are similar to the frequency observed for the unlinked murine Hbb-1 and Hba genes in erythroid cells (30) . We estimated that KG1 cells contain at least 600-700 RNA polymerase II foci from immunofluorescence analysis (Fig. S9) . Optical limitations mean that this is almost certainly an underestimate and the data are consistent with the range of 2,000-3,000 per cell reported previously (18) . Given that the number of genes expressed in CD34 + cells is estimated to be ∼15,000 (38), it is inevitable that multiple transcription units will share common transcription factories. Notably, a lower frequency of transcriptional colocalization with MLL was observed for a locus that is rarely associated with MLL translocation (DCP1A) and one not associated with MLL translocation (UGCG; Fig. 1G ). This is consistent with the notion that frequencies of juxtaposition of transcribing loci contribute to observed translocation frequencies in acute leukemias. We observed similar colocalization frequencies for a second cell line, Nalm-6, but the frequency of juxtaposition was lower for the topoisomerase IIβ null line Nalm-6 TOP2B−/− than the wild type (Fig. 1G) . This difference was also observed in DNA-FISH experiments, where the percentage of nuclei containing MLL and AF9 loci within 1 μm of each other was 50% lower in Nalm-6 TOP2B−/− cells than in WT cells (P > 0.05) (Fig. 1I) . Thus, topoisomerase IIβ status appears to affect the frequency of MLL and AF9 association in the nucleus and thus has the potential to affect translocation rates through this mechanism as well as by mediating the genotoxic effects of etoposide (Figs. 2 and 3) .
A key outstanding question is why the MLL breakpoints occur in such a restricted zone in t-AL compared with de novo acute leukemia. The clustering of therapy-related and neonatal breakpoints in the telomeric 1 kb of the BCR suggests a specific mechanism for the generation of these translocations that may be different from the etiology of other acute leukemias. From previous reports, this region appears sensitive to etoposide-induced cleavage (15, 35, 39) , although this may be related to early CAD-mediated apoptotic cleavage rather than direct topoisomerase-mediated breaks (35, 40, 41) . We find that, whereas etoposide-induced, topoisomerase-mediated cleavage does occur at the telomeric 1 kb of the BCR after short (1 h) drug exposure, cleavage also occurs at other sites in the region (Figs. S7 and S8) , suggesting other factors such as chromatin accessibility or events downstream of DNA DSB production also play a role in the mechanism of translocation in t-AML that favors the telomeric region of the BCR (14, 15, 39) . This is consistent with our finding that, whereas etoposide induces equivalent numbers of genomic DSBs in WT and TOP2B null cells, significantly fewer MLL breaks and MN are induced in the null cells (Figs. 2, 3, and 4) . Open chromatin, cryptic promoter activity, and CTCF binding in this region support a transcription-related mechanism, which combined with our RNA-FISH data (Fig. 1) involves the sharing of sites of transcription leading to the opportunity for incorrect repair of breaks in two different transcription units engaged in the same transcription factory. It has recently become clear that topoisomerase IIβ has a role in transcription and the data reported herein highlights the requirement for topoisomerase IIβ in mediating the genotoxic effects of etoposide in Nalm-6 cells. The possibility that these two findings are linked is an intriguing area for further study, which could provide better understanding of the mechanism of chromosomal translocations in acute leukemia.
Material and Methods
Cells and Reagents. KG1 cells were obtained from ECACC and were maintained in IDMEM supplemented with 20% FCS. Nalm-6 TOP2B−/− and Nalm-6 TOP2A+/− were described previously (12); these and their wild-type counterparts (Nalm-6) were grown in RPMI containing 10% (vol/vol) FCS. All cells were cultured at 37°C in a humidified atmosphere containing 5% CO 2 .
MLL Break-Apart DNA FISH. Detection of MLL breaks was performed using a commercial diagnostic FISH probe, (Vysis LSI MLL Dual Color Break Apart Probe; Abbott Molecular). Details can be found in SI Materials and Methods.
RNA-FISH. RNA-FISH was carried out using single-stranded intronic antisense probes (SI Materials and Methods).
Topoisomerase IIα and IIβ Chromatin Immunoprecipitation. Chromatin immunoprecipitation was performed using the EZ-Magna ChIP A kits (Millipore). Details of the protocol used are given in SI Materials and Methods.
γH2AX Assays. Control or etoposide-treated cells (5 μM, 2 h) were spread onto poly-L-lysine-coated slides and cells were processed for γH2AX immunofluorescence as described previously (42) . The experiment was repeated three to four times. Images were recorded using a 60× objective and extended focus images were scored for γH2AX foci. Images were also recorded at low magnification (10×) for quantitative fluorescence as described previously for the TARDIS assay (43) .
In-Cell Cleavage Analysis. Chromatin was prepared from control or etoposidetreated cells (100 μM, 1 h treatment) and immunoprecipitated as for ChIP analysis (above), but in the absence of formaldehyde, to recover chromatin fragments terminating in topoisomerase II-DNA covalent complexes. Recovered chromatin was prepared for Illumina paired-end library construction as described in SI Materials and Methods.
Micronucleus Assay. Cells were exposed to etoposide or solvent for 3 h. Drug was then washed out and cells were incubated in medium for 40 h to allow cells to go through one mitosis but not two. Cells were spotted onto poly-Llysine slides, fixed in methanol, air dried, and then rehydrated in Weisse buffer pH 6.4 (VWR) and stained with acridine orange (1.4 mg/mL) before washing in fresh Weisse buffer. Slides were then air dried and analyzed for micronuclei by fluorescence microscopy. Scoring was done according to criteria described (31) .
ACKNOWLEDGMENTS. This work was supported by Leukaemia and Lymphoma Research (formerly Leukaemia Research Fund) Specialist
